Tom Lillie completed his undergraduate training at Brasenose College, University of Oxford, where he was awarded a first-class degree in pharmacology, cell biology and immunology, before earning his doctorate from the Department of Physiology at University College of London. He then completed his medical education at University College London Medical School, receiving honours distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. Tom has previously held senior oncology roles in Amgen and MSD, most recently as VP and Head of Oncology Global Medical Affairs. In these roles has led global, regional and affiliate medical teams, encompassing both clinical development and medical affairs functions. He has extensive experience in clinical research in phase 2 – phase 4, focusing on the development, registration, reimbursement and commercialisation of multiple oncology products (biologic, targeted, immuno-oncology and an oncolytic virus). During his clinical and industry career he has specialised in oncology & haematology, but has also worked in cardiovascular, vaccine and neurologic disease areas.